Publications by authors named "Audrey M Gonzalez"

Article Synopsis
  • Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) shows clinical efficacy in metastatic melanoma, with a 42% overall response rate across 74 patients.
  • Prior treatment with anti-CTLA4 impacts TIL ACT outcomes negatively, leading to shorter survival and reduced response rates, particularly in patients who were pre-treated with this checkpoint inhibitor.
  • Baseline serum IL9 levels may predict response to TIL ACT, suggesting a potential strategy for sequencing immunotherapies in treating melanoma patients.
View Article and Find Full Text PDF
Article Synopsis
  • The study proposes a new approach to improve tumor-infiltrating lymphocyte (TIL) therapy by speeding up the expansion process through a combination of T-cell receptor activation and stimulation of specific markers (CD137/4-1BB and IL-2).
  • This 3-signal method resulted in rapid and consistent growth of CD8 TIL from melanoma tumors, achieving successful expansion in all cultures tested in less than three weeks.
  • The enhanced TILs showed the ability to recognize and target melanoma cells, presenting a significant advancement for the application of TIL therapy in difficult-to-treat cancers like uveal melanoma.
View Article and Find Full Text PDF

Following the clinical success achieved with the first generation of adoptive cell therapy (ACT) utilizing expanded tumor-infiltrating lymphocytes (TILs), the second and third generations of TIL ACT are evolving toward the use of genetically modified TIL. TIL therapy generally involves the transfer of a high number of TIL, ranging from 10 to 10 cells. One of the technical difficulties in genetically modifying TIL, using a retroviral vector, is the ability to achieve large expansion of transduced TIL, while keeping the technique suitable to a Good Manufacturing Practices (GMP) environment.

View Article and Find Full Text PDF